Isocitrate dehydrogenase wild-type (IDHwt) lower-grade gliomas of histologic grades II and III follow heterogeneous clinical outcomes, which necessitates risk stratification. We aimed to evaluate whether radiomics from MRI would allow prediction of overall survival in patients with IDHwt lower-grade gliomas and to investigate the added prognostic value of radiomics over clinical features.
Preoperative MRIs of 117 patients with IDHwt lower-grade gliomas from January 2007 to February 2018 were retrospectively analyzed. The external validation cohort consisted of 33 patients from The Cancer Genome Atlas. A total of 182 radiomic features were extracted. Radiomics risk scores (RRSs) for overall survival were derived from the least absolute shrinkage and selection operator (LASSO) and elastic net. Multivariable Cox regression analyses, including clinical features and RRSs, were performed. The integrated areas under the receiver operating characteristic curves (iAUCs) from models with and without RRSs were calculated for comparisons. The prognostic value of RRS was assessed in the validation cohort.
The RRS derived from LASSO and elastic net independently predicted survival with hazard ratios of 9.479 (95% confidence interval [CI], 3.220–27.847) and 6.148 (95% CI, 3.009–12.563), respectively. Those RRSs enhanced model performance for predicting overall survival (iAUC increased to 0.780–0.797 from 0.726), which was externally validated. The RRSs stratified IDHwt lower-grade gliomas in the validation cohort with significantly different survival.
Radiomics has the potential for noninvasive risk stratification and can improve prediction of overall survival in patients with IDHwt lower-grade gliomas when integrated with clinical features.
• Isocitrate dehydrogenase wild-type lower-grade gliomas with histologic grades II and III follow heterogeneous clinical outcomes, which necessitates further risk stratification.
• Radiomics risk scores derived from MRI independently predict survival even after incorporating strong clinical prognostic features (hazard ratios 6.148–9.479).
• Radiomics risk scores derived from MRI have the potential to improve survival prediction when added to clinical features (integrated areas under the receiver operating characteristic curves increased from 0.726 to 0.780–0.797).
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Integrated area under the receiver operating characteristic curve
Isocitrate dehydrogenase wild-type
Karnofsky Performance Status
Receiver operating characteristic
Radiomics risk score
The Cancer Genome Atlas
World Health Organization
Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498
Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722
Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729
Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508
Reuss DE, Kratz A, Sahm F et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417
Aibaidula A, Chan AK, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337
Chan AK, Yao Y, Zhang Z et al (2015) TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol 28:177–186
Chan AK, Yao Y, Zhang Z et al (2015) Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget 6:20885–20901
Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805–810
Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006
Kickingereder P, Gotz M, Muschelli J et al (2016) Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res 22:5765–5771
Bae S, Choi YS, Ahn SS et al (2018) Radiomic MRI phenotyping of glioblastoma: improving survival prediction. Radiology 289:797–806
Hu LS, Ning S, Eschbacher JM et al (2017) Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol 19:128–137
Kickingereder P, Burth S, Wick A et al (2016) Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology 280:880–889
Zhou H, Vallieres M, Bai HX et al (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 19:862–870
Liu X, Li Y, Qian Z et al (2018) A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas. Neuroimage Clin 20:1070–1077
Zhang X, Tian Q, Wang L et al (2018) Radiomics strategy for molecular subtype stratification of lower-grade glioma: detecting IDH and TP53 mutations based on multimodal MRI. J Magn Reson Imaging 48:916–926
Ren Y, Zhang X, Rui W et al (2019) Noninvasive prediction of IDH1 mutation and ATRX expression loss in low-grade gliomas using multiparametric MR radiomic features. J Magn Reson Imaging 49:808–817
Li Y, Qian Z, Xu K et al (2018) MRI features predict p53 status in lower-grade gliomas via a machine-learning approach. Neuroimage Clin 17:306–311
Liu X, Li Y, Li S et al (2019) IDH mutation-specific radiomic signature in lower-grade gliomas. Aging (Albany NY) 11:673–696
Pedano N, Flanders A, Scarpace L et al (2016) Radiology data from the cancer genome atlas low grade glioma [TCGA-LGG] collection. Cancer Imaging Archive
Tustison NJ, Avants BB, Cook PA et al (2010) N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 29:1310–1320
Sled JG, Zijdenbos AP, Evans AC (1998) A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17:87–97
Shinohara RT, Sweeney EM, Goldsmith J et al (2014) Statistical normalization techniques for magnetic resonance imaging. Neuroimage Clin 6:9–19
Fedorov A, Beichel R, Kalpathy-Cramer J et al (2012) 3D slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging 30:1323–1341
Taha AA, Hanbury A (2015) Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool. BMC Med Imaging 15:29
Lee M, Woo B, Kuo MD, Jamshidi N, Kim JH (2017) Quality of radiomic features in glioblastoma multiforme: impact of semi-automated tumor segmentation software. Korean J Radiol 18:498–509
van Griethuysen JJM, Fedorov A, Parmar C et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104–e107
Takano S, Tian W, Matsuda M et al (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123
Choi J, Lee EY, Shin KJ, Minn YK, Kim J, Kim SH (2013) IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for the diagnostic procedure. Pathol Res Pract 209:284–290
Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33:1–22
Microsoft HO (2017) glmnetUtils: utilities for ‘Glmnet’. R package version 1.1. Available via https://CRAN.R-project.org/package=glmnetUtils
Simon N, Friedman J, Hastie T, Tibshirani R (2011) Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw 39:1–13
Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC curves. Biometrics 61:92–105
Akaike H (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control 19:716–723
Contal C, O’Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30:253–270
Kickingereder P, Neuberger U, Bonekamp D et al (2018) Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. Neuro Oncol 20:848–857
Ingrisch M, Schneider MJ, Norenberg D et al (2017) Radiomic analysis reveals prognostic information in T1-weighted baseline magnetic resonance imaging in patients with glioblastoma. Invest Radiol 52:360–366
Soni N, Priya S, Bathla G (2019) Texture Analysis in Cerebral Gliomas: A Review of the Literature. AJNR Am J Neuroradiol 40:928–934
Suárez-García JG, Hernández-López JM, Moreno-Barbosa E, de Celis-Alonso B (2020) A simple model for glioma grading based on texture analysis applied to conventional brain MRI. bioRxiv. https://doi.org/10.1101/2020.01.29.924712
Meyer M, Reimand J, Lan X et al (2015) Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A 112:851–856
Liu Y, Zhang X, Feng N et al (2018) The effect of glioblastoma heterogeneity on survival stratification: a multimodal MR imaging texture analysis. Acta Radiol 59:1239–1246
Yang D, Rao G, Martinez J, Veeraraghavan A, Rao A (2015) Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Med Phys 42:6725–6735
The authors acknowledge M.S. Haesol Shin from the Department of Biostatistics and Computing, Yonsei University College of Graduate, for her support in statistical analysis. We also acknowledge Sang Wook Kim from the Department of Biomedical Engineering, Korea University, and Dongmin Choi from the Department of Computer Science, Yonsei University, for their support in radiomic feature extraction.
This research received funding from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communication Technologies & Future Planning (2017R1D1A1B03030440).
The scientific guarantor of this publication is Sung Soo Ahn.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise. Kyunghwa Han, Ph.D., from the Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, has significant statistical expertise and one of the authors.
Written informed consent was waived by the Institutional Review Board.
Institutional Review Board approval was obtained.
• diagnostic or prognostic study
• performed at one institution
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Park, C.J., Han, K., Kim, H. et al. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas. Eur Radiol 30, 6464–6474 (2020). https://doi.org/10.1007/s00330-020-07089-w
- Isocitrate dehydrogenase
- Magnetic resonance imaging